Beacon Equity Researches: Sanofi-Aventis, Amazon, Yahoo, Johnson & Johnson, Novavax and NexMed
DALLAS, July 1 /PRNewswire/ -- Investment opinion and research leader BeaconEquity.com announces the availability of stock alerts on leading, active stocks in today's news. Each stock alert highlights recent news, trading activity, technical analysis and relevant market research you need to kn...Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008
...uary 2009, the Company acquired the U.S. rights to nexmed Inc.'s ("NexMed") topically applied alprostadil cr...previous license agreement between the Company and nexmed relating to the product was terminated. The Company paid nexmed an upfront fee of $2.5 million, which will be incl...Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
...t, we obtained the exclusive U.S. rights to develop and market NexMed's topically applied alprostadil cream for the treatment of erectile dysfunction. nexmed submitted an NDA with the FDA on September 21, 2007 and is awaiting confirmation of acceptance of its submission. We paid an upfront fee of $0.5 milli...David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
...spent eight years in various drug development roles. Dr. Tierney is also a member of the board of directors of Catalyst Pharmaceuticals Partners, Inc, nexmed Inc and serves as chairman of the board of directors of Bioject Inc. "Thomas, McNerney & Partners has a great platform in biopharmaceuticals," said ...